You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Summary of patient and disease characteristics by individual patient (N = 12)

From: A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Characteristic Mediand Patient
1 2 3 4 5 6 7 8 9 10 11 12
Age 66.8 69 59 85 54 57 61 81 70 76 82 61 64
T Stage T3c T2a T3b T2b T3c T2b T2a T4 T2a T2a T3a T1b
N Stage N0 NX N0 NX N1 NX N1 N1 N1 N0 N1 N0
Laterality L R R R R R R R R L L L
Tumor Size (cm)a 8.7 9.3 7 8.9 11.9 11.2 13.8 7.3 10 7.9 7.5 9.8 4.8
Radiation Dose (Gy) / Fractions 25/5 25/5 25/5 30/5 30/5 30/5 30/5 30/5 35/5 30/5 35/5 35/5
∆ CrCl (mL/min.) −13.5 −13.5 35.9 −12.1 −4.6 NR −48.2 NR NR −36.6 −24.7 −54 17.5
Local Response (%)b −17.3 −11.8 −17.1 −30.3 −25.2 −25.9 −5.8 NR NR −54.4c + 5.3 −17.5 −14.6
Time to Systemic Progression (months) 3.9d 4.34 0.7 10.9 20.5 0.6 0.9 0.8 0.5 12.2 15.0 5.2 3.9
Systemic Therapy P P P,E T S S
Survival (months) 6.7d 4.9 10.2 16.4 43.6 1.5 3.2 1.3 2.4 13.6 22e 6.7 4.6
  1. L: left kidney, R: right kidney, HT – helical tomotherapy, IMRT: intensity modulated radiotherapy, VMAT: volumetric arc therapy, NR: not reported, CrCl: Creatinine clearance, - change, P: pazopanib, E: everolimus, T: temsirolimus, S: sunitinib. aLongest tumor dimension on CT scan; bMaximal reduction (−) or increase (+) in primary renal tumor size following SABR, expressed as percent of initial size; cPt. 9 also underwent renal embolization (post-SABR) for refractory hematuria; dMedian overall survival and time to systemic progression calculated using Kaplan-Meier method (95% CIs: 1.48–16.43 and 0.7–10.7, respectively); eAlive at last follow-up